IP Library Granted Patent US 9,114,190
Granted Patent B2
US 9,114,190 · App. 13/762,471 · Granted Aug 25, 2015

Regeneration of spinal discs

Inventor: Mark Flood (St. Petersburg, FL)
Assignee: Laser Spine Institute, LLC
A61L27/3658A61K35/18A61K35/19A61K35/28A61K35/30A61K35/32A61K35/35A61K38/1875A61K38/30A61K38/39A61L27/3817A61L27/3834
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,114,190
App. No.
13/762,471
Granted
Aug 25, 2015
Kind
B2
Abstract

Compositions and processes for the effective and efficient regeneration of spinal discs are provided. These compositions contain stem cells, donor cells, and platelet plasma compositions. By using these compositions, there is an increased likelihood of acceptance and proper cell differentiation.

Claims (24)

1. A process for regenerating a disc in a person in need of disc regeneration, said process comprising:

(a) harvesting bone marrow from the person;

(b) generating bone marrow aspirate and a platelet plasma composition from the bone marrow, wherein the bone marrow aspirate comprises mesenchymal stem cells, plasma, platelets and red blood cells;

(c) harvesting disc chondrocytes and an extracellular matrix from non-degenerative disc tissue of the person;

(d) combining the bone marrow aspirate and the disc chondrocytes to form a composition under conditions that permit the mesenchymal stem cells to begin differentiation through socialization due to cell to cell signaling; and

(e) administering the composition to a disc of the person in need of disc regeneration.

2. The process of claim 1 further comprising administering a scaffold to the person.

3. The process according to claim 2 , wherein the scaffold comprises at least one substance selected from the group consisting of platelet poor plasma, hyaluronic acid, fibrin glue and a flowable wound matrix.

4. The process according to claim 2 , wherein the scaffold comprises atelocollagen, hyaluronic acid and PEG-PLA.

5. The process of according to claim 1 further comprising mixing the chondrocytes, the extra cellular matrix, the bone marrow aspirate and the platelet plasma composition with stem cells derived from adipose tissue.

6. The process according to claim 5 , wherein the adipose tissue is subcutaneous fat.

7. The process according to claim 6 , wherein the mesenchymal stem cells from bone marrow aspirate and the stem cells from adipose tissue each contribute 40-60% of the total stem cells by volume.

8. The process according to claim 1 , wherein said step (c) harvesting comprises morselizing donor disc material.

9. The process according to claim 1 , wherein said step (c) harvesting comprises extruding the donor disc material.

10. The process of claim 1 further comprising separating blood plasma into platelet rich plasma and platelet poor plasma, and exposing the platelet rich plasma to conditions that lyse membranes of cells in the platelet rich plasma to form a lysate, wherein the platelet plasma composition comprises the lysate.

11. The process according to claim 1 , wherein the composition further comprises LIM mineralization protein (LMP)-1.

12. The process according to claim 1 , wherein said combining further comprises adding calcium chloride.

13. The process according to claim 12 , wherein said combining further comprises adding thrombin.

14. The process according to claim 1 , wherein said combining further comprises adding insulin-like growth factor-1.

15. The process according to 1 , wherein said combining further comprises adding bone morphogenic protein.

16. The process according to claim 1 , wherein said combining further comprises adding Sox-9.

17. The process according to claim 1 , wherein said combining further comprises adding genipin.

18. The process according to claim 1 , further comprising photo-activating the composition.

19. The process according to claim 18 , wherein said photo-activating is under conditions that increase the presence of Interleukin-1 Receptor Antagonist.

Assignments (2)
SECURITY INTEREST Recorded Jul 2, 2015
From: LASER SPINE INSTITUTE, LLC
To: TEXAS CAPITAL BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 035972/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2013
From: FLOOD, MARK
To: LASER SPINE INSTITUTE, LLC
Reel/Frame 030120/0869 →
Continuity (1)
Related Publication 20140227240A1 · Aug 14, 2014